IP Library Granted Patent US 10,683,370
Granted Patent B2
US 10,683,370 · App. 15/977,754 · Granted Jun 16, 2020

Methods for making saccharide-protein glycoconjugates

Inventors: Allan James Saul (Castellina, IT); Francesca Micoli (Florence, IT)
Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
C08B37/0006A61K39/02A61K39/0275A61K39/095A61K39/385A61K47/646A61K47/6415C07K14/34C07K16/1285C07K16/44C08B37/0003C08B37/006C08B37/0063C08B37/0081A61K2039/6037C07K2317/734Y02A50/482
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,683,370
App. No.
15/977,754
Granted
Jun 16, 2020
Kind
B2
Abstract

The invention provides a process for the reductive amination of a carbonyl group at the reducing terminus of a polysaccharide, wherein the reductive amination is carried out at a pH between 4 and 5. The invention also provides a process for preparing a conjugate of a polysaccharide and a carrier molecule, comprising the steps of: (a) coupling the polysaccharide to a linker, to form a polysaccharide-linker compound in which the free terminus of the linker is an ester group; and (b) reacting the ester group with a primary amine group in the carrier molecule, to form a polysaccharide-linker-carrier molecule conjugate in which the linker is coupled to the carrier molecule via an amide linkage. The invention also provides a process for reducing contamination of a polysaccharide-linker compound with unreacted linker, comprising a step of precipitating unreacted linker under aqueous conditions at a pH of less than 5. The invention also provides polysaccharide-linker-carrier molecule conjugates and intermediate compounds obtained or obtainable by these processes.

Claims (34)

1. A polysaccharide-linker intermediate of the formula:

wherein OAg is an O-antigen-core from a lipopolysaccharide which has been coupled using a carbonyl group at the reducing terminus.

2. The polysaccharide-linker intermediate of claim 1 , wherein the lipopolysaccharide is from a Salmonella bacterium.

3. The polysaccharide-linker intermediate of claim 2 , wherein the lipopolysaccharide is from Salmonella serogroups A, B or D.

4. A polysaccharide antigen conjugate prepared by a process comprising the steps of:

(a1) reacting a carbonyl group at a reducing terminus of a polysaccharide with Y 1 of an additional linker of Formula 1,

wherein Formula 1 is Y 1 -L-Y 2 ,

wherein L is a linking moiety, Y 1 and Y 2 are each —NHNH 2 groups;

(a2) reacting Y 2 of the additional linker with a linker, to form a polysaccharide-additional linker-linker compound in which the free terminus of the linker is an ester group; and

(b) reacting the ester group of the linker with a primary amine group in a carrier molecule, to form a polysaccharide-additional linker-linker-carrier molecule conjugate in which the linker is coupled to the carrier molecule via an amide linkage.

5. The polysaccharide antigen conjugate of claim 4 , wherein the polysaccharide comprises an O-antigen from a lipopolysaccharide.

6. The polysaccharide antigen conjugate of claim 5 , wherein the polysaccharide also comprises a core domain.

7. The polysaccharide antigen conjugate of claim 5 , wherein the lipopolysaccharide is from a Gram negative bacterium.

8. The polysaccharide antigen conjugate of claim 6 , wherein the lipopolysaccharide is from a Gram negative bacterium.

9. The polysaccharide antigen conjugate of claim 7 , wherein the lipopolysaccharide is from a Salmonella bacterium.

10. The polysaccharide antigen conjugate of claim 8 , wherein the lipopolysaccharide is from a Salmonella bacterium.

11. The polysaccharide antigen conjugate of claim 4 , wherein the carrier molecule is CRM 197 .

12. The polysaccharide antigen conjugate of claim 4 , wherein the additional linker is adipic acid dihydrazide (ADH).

13. The polysaccharide antigen conjugate of claim 4 , wherein the polysaccharide comprises an O-antigen and a core from a lipopolysaccharide from a Salmonella bacterium, wherein the carrier molecule is CRM 197 , wherein the additional linker is adipic acid dihydrazide (ADH), wherein the linker is adipic acid N-hydroxysuccinimide diester (SIDEA) and wherein the additional linker is coupled using a carbonyl group at the reducing terminus of the polysaccharide.

14. A process for preparing a conjugate of a polysaccharide and a carrier molecule comprising the steps of:

(a1) reacting a carbonyl group at a reducing terminus of the polysaccharide with Y 1 of an additional linker of Formula 1,

wherein Formula 1 is Y 1 -L-Y 2 ,

wherein L is a linking moeity, Y 1 and Y 2 are each —NHNH 2 groups;

(a2) reacting Y 2 with the linker SIDEA, to form a polysaccharide-additional linker-linker compound in which the free terminus of the linker is an ester group; and

(b) reacting the ester group of the linker with a primary amine group in a carrier molecule, to form a polysaccharide-additional linker-linker-carrier molecule conjugate in which the linker is coupled to the carrier molecule via an amide linkage.

15. The process of claim 14 , wherein the polysaccharide comprises an O-antigen from a lipopolysaccharide.

16. The process of claim 15 , wherein the polysaccharide also comprises a core domain.

17. The process of claim 15 , wherein the lipopolysaccharide is from a Gram negative bacterium.

18. The process of claim 16 , wherein the lipopolysaccharide is from a Gram negative bacterium.

19. The process of claim 17 , wherein the lipopolysaccharide is from a Salmonella bacterium.

20. The process of claim 18 , wherein the lipopolysaccharide is from a Salmonella bacterium.

21. The process of claim 14 , wherein the carrier molecule is CRM 197 .

22. The process of claim 14 , wherein the additional linker is adipic acid dihydrazide (ADH).

23. The process of claim 14 , wherein the polysaccharide comprises an O-antigen and a core from a lipopolysaccharide from a Salmonella bacterium, wherein the carrier molecule is CRM 197 , wherein the additional linker is adipic acid dihydrazide (ADH), wherein the linker is adipic acid N-hydroxysuccinimide diester (SIDEA) and wherein the additional linker is coupled using a carbonyl group at the reducing terminus of the polysaccharide.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2024
From: SAUL, ALLAN; MICOLI, FRANCESCA
To: NOVARTIS VACCINES INSTITUTE FOR GLOBAL HEALTH S.R.L.
Reel/Frame 069158/0923 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2024
From: NOVARTIS VACCINES INSTITUTE FOR GLOBAL HEALTH S.R.L.
To: NOVARTIS AG
Reel/Frame 069159/0148 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2024
From: NOVARTIS AG
To: GLAXOSMITHKLINE BIOLOGICALS SA
Reel/Frame 069159/0273 →
Continuity (4)
Continuation 15150302 · May 9, 2016
Continuation 14343351
Provisional Application 61534751 · Sep 14, 2011
Related Publication 20180334515A1 · Nov 22, 2018